Publications
2022
Structure of human NTCP reveals the basis of recognition and sodium-driven transport of bile salts into the liver.,
Liu, Hongtao, Irobalieva Rossitza N., Bang-Sørensen Rose, Nosol Kamil, Mukherjee Somnath, Agrawal Parth, Stieger Bruno, Kossiakoff Anthony A., and Locher Kaspar P.
, Cell Res, 2022 Aug, Volume 32, Issue 8, p.773-776, (2022)
2021
Structures of ABCB4 provide insight into phosphatidylcholine translocation.,
Nosol, Kamil, Bang-Sørensen Rose, Irobalieva Rossitza N., Erramilli Satchal K., Stieger Bruno, Kossiakoff Anthony A., and Locher Kaspar P.
, Proc Natl Acad Sci U S A, 2021 Aug 17, Volume 118, Issue 33, (2021)
Publications
- Characterization of synthetic antigen binding fragments targeting Toc75 for the isolation of TOC in A. thaliana and P. sativum.
- Development of a universal nanobody-binding Fab module for fiducial-assisted cryo-EM studies of membrane proteins.
- Development, structure, and mechanism of synthetic antibodies that target claudin and Clostridium perfringens enterotoxin complexes.
- Engineering of a synthetic antibody fragment for structural and functional studies of K+ channels.
- Isoform- and ligand-specific modulation of the adhesion GPCR ADGRL3/Latrophilin3 by a synthetic binder.
- Quaternary structure independent folding of voltage-gated ion channel pore domain subunits.
- Structural basis for assembly and lipid-mediated gating of LRRC8A:C volume-regulated anion channels.
- Structure of an AMPK complex in an inactive, ATP-bound state.
- Structure of human NTCP reveals the basis of recognition and sodium-driven transport of bile salts into the liver.
- Structure, sequon recognition and mechanism of tryptophan C-mannosyltransferase.
- Structures of ABCB4 provide insight into phosphatidylcholine translocation.
- Structures of atypical chemokine receptor 3 reveal the basis for its promiscuity and signaling bias.
- Synthetic Antibodies Detect Distinct Cellular States of Chromosome Passenger Complex Proteins.
- Targeting a proteolytic neoepitope on CUB domain containing protein 1 (CDCP1) for RAS-driven cancers.